1. Introduction {#s0005}
===============

Postsynaptic striatal dopamine type-2 receptors (D~2~Rs) modulate the striatopallidal and the striatocortical signaling pathways in the basal ganglia output nuclei. In Parkinson\'s disease (PD), stimulation of these pathways is affected due to the progressive degeneration of dopaminergic neurons ([@bb0150], [@bb0070]), leading to alterations in synaptic dopamine levels and the development of motor symptoms ([@bb0110]), cognitive symptoms ([@bb0155], [@bb0160]), and dyskinesias ([@bb0135]). Although long-term changes in D~2~R availability may be also implicated ([@bb0010]), it is unclear how these changes are affected by the progression of the disease and the dopaminergic treatment in patients with PD.

\[^11^C\]raclopride PET is a selective marker and a valuable tool for investigating D~2~R availability in vivo ([@bb0085]). \[^11^C\]raclopride PET studies in *de novo* PD patients have reported an increase in D~2~R availability in the putamen contralateral to the more affected limbs, while the D~2~R availability in the caudate remains intact ([@bb0145], [@bb0190]). A combined PET study with \[^18^F\]fluoro-[l]{.smallcaps}-dopa (F-DOPA), a marker of pre-synaptic dopamine storage capacity, and \[^11^C\]raclopride reported inverse correlations between reduced F-DOPA and increased post-synaptic D~2~R in *de novo* PD ([@bb0165]). Therefore, in early *denovo* PD, upregulation of post-synaptic D~2~R in the putamen could be a compensatory mechanism in response to depletion of pre-synaptic dopaminergic terminals and synaptic dopamine levels. However, as PD progresses D~2~R availability normalizes in the putamen, but availability in the caudate is reduced ([@bb0010], [@bb0190], [@bb0035], [@bb0045]). As the disease progresses and increasing degeneration of nigrostriatal dopamine neurons occurs this compensatory mechanism fails; leading to decreased D~2~R availability in caudate. Furthermore, after 3--5 years of levodopa treatment, \[^11^C\]raclopride binding is significant reduced in the putamen and caudate compared to baseline ([@bb0010]). These findings suggest that down-regulation of striatal D~2~R in PD may be induced by chronic dopaminergic treatment. Alterations in D~2~R function have been also suggested to play a role in mechanisms underlying dyskinesias in PD ([@bb0020], [@bb0060]).

Here we used \[^11^C\]raclopride PET to explore the integrity of striatal D~2~R ligand binding and its relevance to the development of clinical symptoms and the chronic exposure to dopaminergic treatment in a group of patients with PD.

2. Materials and methods {#s0010}
========================

2.1. Participants {#s0015}
-----------------

We studied 68 patients with idiopathic PD according to the UK Brain Bank clinical diagnostic criteria. All PD patients were receiving dopamine replacement therapy. To assess the effect of dopamine agonist treatment, PD patients were divided into two groups, those who were receiving dopamine agonists (n = 46; either Ropinerole or Pramipexole, not in extended release) and patients who had never received treatment with dopamine agonists (n = 22). Apart from levodopa and dopamine agonists, PD patients were not on any other medication with known action on dopamine receptors. Twelve healthy individuals matched for age and gender, with no history of neurological or psychiatric illness served as the healthy control group. All subjects were non-demented ([Table 1](#t0005){ref-type="table"}).Table 1Clinical characteristics of Parkinson\'s disease patients and healthy controls.Table 1Parkinson\'s disease patientsHealthy controlsNo of subjects6812Sex52 M/16F10 M/2FAge (years ± SD)62.8 (± 9.1)63.3 (± 7.0)Disease duration (years ± SD)[a](#tf0005){ref-type="table-fn"}10.71 (± 6.4)--H&Y OFF (mean ± SD)2.8 (± 0.94)--UPDRS Part-III OFF (mean ± SD)42.0 (± 13.0)--UPDRS Part-III ON (mean ± SD)20.8 (± 8.9)--MMSE (mean ± SD)29.2 (± 1.4)29.4 (± 0.7)BDI-II (mean ± SD)13.7 (± 8.7)3.1 (± 2.6)Duration of dopaminergic therapy (years ± SD)6.5 (± 4.1)--Duration of dopamine agonist (DA) treatment (years ± SD)4.3 (± 3.7)--Duration of levodopa ([l]{.smallcaps}-DOPA) treatment (years ± SD)5.5 (± 4.2)--Daily LED~[l]{.smallcaps}-DOPA~ (mg ± SD)739.0 (± 31.9)--Daily LED~DA~ (mg ± SD)173.8 (± 180.4)--Daily LED~TOTAL~ (mg ± SD)911.0 (± 721.6)--Lifetime LED~[l]{.smallcaps}-DOPA~ (g ± SD)991.5 (± 057.6)--Lifetime LED~DA~ (g ± SD)299.4 (± 391.4)--Lifetime LED~TOTAL~ (g ± SD)1291.0 (± 1250.8)--[^1]

2.2. Clinical assessments {#s0020}
-------------------------

PD subjects were staged for disease severity with the Hoehn and Yahr (H&Y) scale and were clinically assessed with the Unified Parkinson\'s Disease Rating Scale (UPDRS), Abnormal Involuntary Movement Scale (AIMS), Mini-Mental State Examination (MMSE) and Beck Depression Inventory (BDI-II). Daily and lifetime dopamine agonist equivalent dose (LED~DA~) and daily and lifetime levodopa equivalent dose (LED~[l]{.smallcaps}-DOPA~) unit calculations were based on theoretical equivalence to levodopa as described previously ([@bb0135], [@bb0130]).

2.3. Scanning procedures {#s0025}
------------------------

All subjects had \[^11^C\]raclopride PET and 1.5-Tesla (T) volumetric MRI in an OFF medication condition after 18 h withdrawal of dopaminergic medications. Long acting dopaminergic medications were withdrawn for 72 h prior to the PET scan. PET imaging was performed at the Cyclotron Unit (Hammersmith Hospital) and \[^11^C\]raclopride radiotracer was supplied by Hammersmith Imanet plc, London, UK. All subjects were scanned using an ECAT HR^+^ (CTI/Siemens 962) 3D PET tomography scanner, with 15.5 cm total axial field of view (FOV). This camera has a mean image transaxial resolution (3D mode) over a 10 cm radius FOV of 6.0 + 0.5 mm and an axial resolution of 5.0 + 0.8 mm ([@bb0025]). All subjects were scanned following administration of \[^11^C\]raclopride as an intravenous bolus, mean dose 250 MBq; PET images were obtained as 20 time frames acquired over 60 min. Volumetric T1-weighted MRI scans were acquired using a 1.5 T MRI (Picker Eclipse, Picker International Inc., Highlands Heights, OH, USA). MRI was performed on the same day as the PET for co-registration of functional images.

The study received ethical approval from the Ethics Committee of Hammersmith, Queen Charlotte\'s and Chelsea and Acton Hospitals. All subjects gave informed written consent in accordance with the Declaration of Helsinki.

2.4. \[^11^C\]raclopride PET image analysis {#s0030}
-------------------------------------------

### 2.4.1. Movement correction {#s0035}

Head movement correction was carried out for all PET images using frame-by-frame realignment ([@bb0095]) with in-house software (c-wave) implemented in Matlab 8.2 (The MathWorks Inc.). Non-attenuated corrected images were denoised using a level 2, order 64 Battle Lemarie wavelet filter ([@bb0195]) followed by realignment using a mutual information algorithm ([@bb0175]). The first three frames were excluded and frame 10 was chosen as the reference frame due to good signal-to-noise ratio. Frames 4--20 of the original time series were resliced and reassembled into a movement-corrected dynamic scan. Decay-corrected time-activity curves were derived and compared to those without movement correction. The amount and timing of any movements were assessed graphically and compared with intrascan notes. Motion correction was applied to all PET data, however since patients were scanned off medication, the effect of head movement has to be considered when interpreting the findings.

### 2.4.2. Parametric images {#s0040}

Parametric \[^11^C\]raclopride non-displaceable binding potential (BP~ND~) images were generated from the dynamic \[^11^C\]raclopride scans using a basis function implementation of the simplified reference tissue model, with the cerebellum as the reference region for non-specific binding ([@bb0065]). PET images were coregistered and resliced to corresponding volumetric T1-weighted MR images using the Mutual Information Registration algorithm in the Statistical Parametric Mapping (SPM, version 8) software package (Wellcome Department of Cognitive Neuroscience, Institute of Neurology, London, UK) implemented in Matlab 8.2.

### 2.4.3. Region of interest analysis {#s0045}

Regions-of-interests (ROIs) were manually delineated on individual co-registered volumetric T1-weigthed MRI images and sampled on parametric PET images, using ANALYZE medical imaging software (Mayo Foundation, Rochester, MN, USA, Version 10). A reliable, robust and repeatable technique was used for manual delineation of ROIs using the Talairach and Tournoux ([@bb0180]) stereotaxic atlas in combination with Duvernoy 3-dimensional sectional atlas ([@bb0050]) on individual coregistered MRIs. The anterior border for the cerebellum was defined by the inferior semilunar lobule, the posterior border and the lateral border was defined by the transverse sinus and the medial border by the cerebellar falx. The anterior border for the caudate nucleus was defined by the lateral ventricle, the posterior border by the internal capsule, the medial border by the lateral ventricle and fornix, and the lateral border was defined by the external capsule. The anterior border for the putamen was defined by the anterior limb of the internal capsule, the posterior border by the posterior limb of the internal capsule, the lateral border by the external capsule/claustrum, and the medial border by the lamina medullaris lateralis. For each subject ROIs were manually delineated in both hemispheres. To minimize possible partial volume effects, anatomical data from high resolution MRI was used to manually delineate specific ROIs ensuring the volume for each ROI was standardized so there was no significant difference in ROI volume across groups. Therefore, reducing the effects of partial volume difference between groups which could account for changes in binding potential.

2.5. MRI volumetric analysis {#s0050}
----------------------------

FreeSurfer\'s image analysis suite (version 6) was used to process individual MRI scans to derive measures of subcortical volumes using automated procedures previous described ([@bb0055]). Subcortical volumes were normalized for intracranial volume using validated methods within the FreeSufer toolkit ([@bb0040]).

2.6. Statistics {#s0055}
---------------

Statistical analysis and graph illustrations were performed with SPSS (version 22) and GraphPad Prism (version 6.0) for MAC OS X, respectively. For all variables, variance homogeneity and Gaussianity were tested with Bartlett and Kolmogorov-Smirnov tests. Repeated-measures analysis of covariance was used to interrogate the association between medication condition and clinical characteristics with D~2~ binding where and \[^11^C\]raclopride BP~ND~ in ROIs was the repeated measure. If a significant interaction was found between a medication and clinical variable and the repeated-measure variable ROI, univariate tests were then carried out on the individual ROIs and resulting p values were corrected for multiple comparisons.

We compared \[^11^C\]raclopride BP~ND~ in the caudate and putamen between PD patients and healthy controls. We assessed the effect of medication on caudate and putamen \[^11^C\]raclopride BP~ND~ in PD patients receiving dopamine agonists (n = 46) compared to PD patients not receiving dopamine agonists (n = 22). To assess the effect of dyskinesias on the integrity of striatal D~2~Rs, PD subjects were categorized into two groups depending on having dyskinesias (n = 38) or not having dyskinesias (n = 30).

\[^11^C\]raclopride BP~ND~ in the caudate and putamen were checked for associations with (a) disease duration, (b) UPDRS Part-III motor scores in ON and OFF medication state, (c) AIMS scores (d) BDI-II scores, (e) dopamine agonist and levodopa treatment duration and (f) amount of daily and lifetime dopamine agonist and levodopa intake. Possible correlations between PET and clinical data were carried out using Pearson *r* and Spearman *ρ* depending on the distribution of each variable; the analyses were repeated including age as covariate. Hochberg-multiple comparison correction was applied for each set of correlations using PPLot (version 1.0) in Matlab ([@bb0200]). All data are presented as mean ± SD and the level of α was set for all comparisons at p \< 0.05, corrected.

3. Results {#s0060}
==========

PD patients had a mean disease duration of 10.7 years and mean 6.5 years of dopaminergic drug treatment ([Table 1](#t0005){ref-type="table"}). PD patients (n = 68) showed a mean 16.7% decrease in caudate \[^11^C\]raclopride BP~ND~ compared to healthy controls (p \< 0.001). In the putamen PD patients showed a mean 3.5% increase in \[^11^C\]raclopride BP~ND~ compared to healthy controls ([Table 2](#t0010){ref-type="table"}). Lower individual caudate \[^11^C\]raclopride BP~ND~ values correlated with longer disease duration (Pearson *r* = − 0.39, p = 0.0012; [Fig. 1](#f0005){ref-type="fig"}). No correlations were found between \[^11^C\]raclopride BP~ND~ and UPDRS or BDI-II scores.Fig. 1Correlation between Parkinson disease duration and caudate postsynaptic dopamine receptor type-2 availability. Inverse correlation between individual caudate \[^11^C\]raclopride BP~ND~ values and disease duration in Parkinson\'s disease patients (n = 68).Fig. 1Table 2Caudate and putamen \[^11^C\]raclopride binding potentials in healthy controls and Parkinson\'s disease patients.Table 2Caudate \[^11^C\]raclopride BP~ND~Putamen \[^11^C\]raclopride BP~ND~Healthy controls (n = 12; mean ± SD)2.27 (± 0.2)2.58 (± 0.2)All PD patients (n = 68; mean ± SD; Δ%)1.89 (± 0.3)[⁎⁎⁎](#tf0015){ref-type="table-fn"}; − 16.7%2.67 (± 0.5); + 3.5%Non-dyskinetic PD patients (n = 30; mean ± SD; Δ%)2.03 (± 0.3)[⁎](#tf0010){ref-type="table-fn"}; − 10.6%2.76 (± 0.4); + 7.0%Dyskinetic PD (n = 38; mean ± SD; Δ%)1.78 (± 0.4)[⁎⁎⁎](#tf0015){ref-type="table-fn"}; − 21.6%2.59 (± 0.5); + 0.4%PD patients receiving NO dopamine agonist treatment (n = 22; mean ± SD; Δ%)2.03 (± 0.3)[⁎](#tf0010){ref-type="table-fn"}; − 10.6%2.89 (± 0.4)\*; + 12.0%PD patients receiving dopamine agonist treatment (n = 46; mean ± SD; Δ%)1.82 (± 0.3)[⁎⁎⁎](#tf0015){ref-type="table-fn"}; − 19.8%2.56 (± 0.5); − 0.8%[^2][^3][^4]

3.1. Volumetric analysis {#s0065}
------------------------

FreeSurfer analysis revealed no volumetric difference in the left and right caudate and putamen between PD patients and healthy controls (p \> 0.10).

3.2. Effect of medication on D~2~R availability {#s0070}
-----------------------------------------------

PD patients on dopamine agonist treatment had no differences in terms of age, cognitive status (MMSE), depression levels (BDI-II), disease stage and burden compared to PD patients who had not received treatment with dopamine agonists (p \> 0.05). We found a significant interaction between dopamine agonist treatment and \[^11^C\]raclopride BP~ND~ in ROIs (p \< 0.001).

Compared to healthy controls, PD patients who had not received treatment with dopamine agonists (n = 22) showed a mean 10.6% decreased caudate \[^11^C\]raclopride BP~ND~ (p \< 0.05) and a mean 12% increased putamen \[^11^C\]raclopride BP~ND~ (p \< 0.05) ([Table 2](#t0010){ref-type="table"}; [Fig. 2](#f0010){ref-type="fig"}A). PD patients on dopamine agonist treatment (n = 46) showed a mean 19.8% decrease in caudate \[^11^C\]raclopride BP~ND~ (p \< 0.001) and a mean 0.8% decrease in putamen \[^11^C\]raclopride BP~ND~ compared to healthy controls ([Table 2](#t0010){ref-type="table"}; [Fig. 2](#f0010){ref-type="fig"}A). In comparisons to PD patients who never received treatment with dopamine agonists, PD patients on dopamine agonist treatment had 9.2% reduced D~2~R availability in the caudate (p \< 0.05) and 12.8% decreased in the putamen (p \< 0.05) ([Fig. 2](#f0010){ref-type="fig"}A). There were no differences in the relation between BP~ND~ and specific dopamine agonists (ropinerole or pramiprexole).Fig. 2Effect of dopamine agonist treatment (A) and presence of dyskinesia (B) on dopamine receptor type-2 receptor availability in the caudate and putamen of patients with Parkinson\'s disease. \*p \< 0.05; \*\*p \< 0.001.Fig. 2

Higher amounts of lifetime dopamine agonist therapy correlated with lower individual \[^11^C\]raclopride BP~ND~ values in the caudate (Spearman *ρ* = − 0.33; p \< 0.05) and in the putamen (Spearman *ρ* = − 0.33; p \< 0.05) of PD patients. These results remained significant after using age as a covariate (caudate *ρ* = − 0.32, p \< 0.05; putamen *ρ* = 0.31, p \< 0.05). Levodopa treatment duration, levodopa daily and lifetime amount were not associated with \[^11^C\]raclopride BP~ND~ values in the caudate and in the putamen.

3.3. Effect of dyskinesias on D~2~R availability {#s0075}
------------------------------------------------

We found a significant interaction between the presence of dyskinesias and \[^11^C\]raclopride BP~ND~ in ROIs (p \< 0.001). PD patients with dyskinesias (n = 38) showed a mean 21.6% decreased caudate \[^11^C\]raclopride BP~ND~ (p \< 0.001) and a mean 0.4% increased \[^11^C\]raclopride BP~ND~ in the putamen compared to healthy controls ([Fig. 2](#f0010){ref-type="fig"}B). PD patients without dyskinesias (n = 30) showed a mean 10.6% decreased caudate \[^11^C\]raclopride BP~ND~ (p \< 0.05) and a mean 7% increased \[^11^C\]raclopride BP~ND~ in the putamen compared to healthy controls ([Table 2](#t0010){ref-type="table"}; [Fig. 2](#f0010){ref-type="fig"}B).

PD patients with dyskinesias had longer disease duration (p \< 0.001), were at a more advanced disease stage (H&Y OFF: p \< 0.001), and had received larger amounts of dopaminergic therapy (LED~total~: p \< 0.001) due to higher levodopa doses (Daily LED~[l]{.smallcaps}-DOPA~: p \< 0.001) compared to PD patients with no dyskinesias. Dopamine agonist intake was no different between PD patients with and without dyskinesias (LED~DA~: p \> 0.10). We found no correlations between individual caudate or putamen \[^11^C\]raclopride BP~ND~ values and AIMS scores. These results were confirmed after controlling for age.

4. Discussion {#s0080}
=============

Our \[^11^C\]raclopride PET findings demonstrate that as PD advances striatal D~2~R availability is altered and is influenced by chronic exposure to dopamine agonist treatment. We found a mean 16.7% loss of D~2~R availability in the caudate and a mean 3.5% increase of D~2~R availability in the putamen in the collective cohort of PD patients studied. In PD patients who had never received treatment with dopamine agonists, D~2~R availability in the caudate was reduced by 10.8% and in the putamen was increased by 12%. In contrast, matched PD patients on dopamine agonist treatment had 9.2% reduced D~2~R availability in the caudate and 12.8% reduction in the putamen compared to PD patients who had not received treatment with dopamine agonists. Higher amounts of dopamine agonist therapy received over PD patient\'s lifetime correlated with reduced D~2~R availability in both caudate and putamen.

*Post mortem* studies have reported normal ([@bb0115]), reduced ([@bb0140]) or increased ([@bb0015]) D~2~R binding in the striatum of PD patients treated with dopaminergic drugs. Previous \[^11^C\]raclopride PET studies have suggested that reductions in caudate D~2~R availability in advanced PD stages may reflect either disease progression or an effect of chronic exposure to dopaminergic therapy ([@bb0005], [@bb0190], [@bb0035], [@bb0045]). Our \[^11^C\]raclopride PET findings suggest that with longer disease duration, D~2~R availability is reduced in the caudate, but not in the putamen. Chronic exposure to dopamine agonist treatment suppresses D~2~R availability in both the caudate and putamen. Dopamine agonists directly target D~2~Rs mimicking the effects of endogenous dopamine. Therefore, down-regulation could be the result of direct competition between \[^11^C\]raclopride and exogenous sources of dopamine, or due to internalization of D~2~R upon dopamine binding leading to reduced availability of \[^11^C\]raclopride binding sites. According to our findings chronic treatment with levodopa does not influence striatal D~2~R availability in PD. It has been shown that chronic exposure to levodopa mainly affects striatal D~1~R availability ([@bb0190]).

Previous \[^11^C\]raclopride PET studies in *de novo* PD patients have shown up to 20% increases in D~2~R availability in the putamen while the D~2~R availability in the caudate was normal ([@bb0190], [@bb0090], [@bb0005]). Further \[^11^C\]raclopride PET studies have shown that as PD progresses, D~2~R availability normalizes in the putamen, but D~2~Rs in the caudate are reduced by around 20% ([@bb0190], [@bb0030], [@bb0035], [@bb0045], [@bb0005]). Our \[^11^C\]raclopride PET findings are compatible with the previous \[^11^C\]raclopride PET studies, showing that D~2~R availability in the striatum is affected by advancing disease stage and suppressed by chronic exposure to dopamine agonist treatment. Dopamine agonist intake may also explain the normalization of putaminal \[^11^C\]raclopride availability and further reductions of caudate \[^11^C\]raclopride availability in advanced PD that has been reported in the previous studies ([@bb0190], [@bb0030], [@bb0035], [@bb0045], [@bb0005]). Dopamine agonists exert their pharmacological effect by directly activating post-synaptic D~2~Rs. Putaminal D~2~R availability returns to within normal levels in PD patients receiving dopamine agonist treatment, counteracting compensatory D~2~R up-regulation observed in the putamen in the absence of dopaminergic treatment. Therefore, early treatment with dopamine agonists could have beneficial effects to slow loss of dopamine terminal function in the putamen. Moreover, another \[^11^C\]raclopride PET study has shown that withdrawal of dopaminergic drugs in previously treated advanced PD patients, undergoing deep brain stimulation of the subthalamic nucleus, resulted in up-regulation of striatal D~2~Rs ([@bb0185]). The authors of this study did not investigate the effect of dopaminergic treatment but our findings suggest this would have been due to withdrawal of dopamine agonist treatment. [Fig. 3](#f0015){ref-type="fig"} illustrates the summary of our findings taken together with the findings from the previous \[^11^C\]raclopride PET studies regarding striatal D~2~R availability in advanced PD patients treated with and without dopamine agonists.Fig. 3Graphical representation of caudate and putamen dopamine receptors type-2 (D~2~R) availability in patients with Parkinson\'s disease. The illustration summarizes our findings together with the findings from the previous \[^11^C\]raclopride PET studies ([@bb0030], [@bb0035], [@bb0090], [@bb0145], [@bb0005], [@bb0010], [@bb0190], [@bb0045]) and shows a linear caudate reduction and a non-linear reduction of D~2~R availability in the putamen as PD progresses. Also, the suppressing effect of chronic dopamine agonist treatment in striatal D~2~R availability in patients with PD. PD = Parkinson\'s disease; D~2~R = dopamine receptor type-2.Fig. 3

Our findings show that longer PD duration correlated with decreased D~2~R availability in the caudate but not in the putamen. These findings suggest that although caudate and putamen D~2~R availability is affected with advancing disease, the loss of D~2~R availability is linear in the caudate and non-linear or linear with a wide variance in the putamen ([Fig. 3](#f0015){ref-type="fig"}). A future longitudinal study, with stratified treatment arms, is required to confirm the true kinetics of putamen D~2~R reductions. The gradual loss of D~2~R availability in the caudate could impact the output signaling pathways from the caudate to the frontal cortex, which are critical for executive functions. A previous \[^11^C\]raclopride PET study has shown that significant attenuation of dopamine release in the caudate was associated with executive deficits in patients with PD ([@bb0155], [@bb0160]). Similar associations between loss of caudate D~2~R availability and cognitive dysfunction have also been reported in Huntington\'s disease ([@bb0105]). Therefore, reduced D~2~R availability in the caudate, likely worsened with dopamine agonist treatment, could have implications for cognitive impairments and executive function deficits in PD patients. Further longitudinal studies, in larger cohorts of PD patients, are required to fully understand the impact of dopamine agonist treatment, and altered D~2~R availability, on cognitive symptomatology in advancing PD.

Our \[^11^C\]raclopride findings also show that PD patients with dyskinesias had greater striatal reductions (11% in the caudate and 6.6% in the putamen) in D~2~R availability compared to PD patients without dyskinesias. PD patients with dyskinesias, however, were more disabled and had more advanced disease. Also, we found no correlations between striatal D~2~R availability and dyskinesias scores and therefore, our findings suggest that the difference in striatal D~2~R availability between dyskinetic and non-dyskinetic PD reflects the more advanced disease in the dyskinetic PD group rather than a direct relationship between the development of dyskinesias and D~2~R availability. These findings are compatible with a previous \[^11^C\]raclopride PET study which demonstrated no association between striatal D~2~R availability and dyskinesias in PD ([@bb0190]). Although it has been postulated that alterations in striatal D~2~Rs may be involved in the development of dyskinesias in PD ([@bb0020], [@bb0060]), it is more likely that loss of dopamine terminals and priming with levodopa play a prominent role. Other non-dopaminergic systems such as the glutamatergic and the serotonergic may play a prominent role in the development of dyskinesias in PD ([@bb0100], [@bb0135]). Lines of evidence suggest that relatively preserved presynaptic serotonergic terminals in the basal ganglia mishandle synaptic levels of dopamine and contribute in the occurrence of dyskinesias in PD ([@bb0135], [@bb0170]).

In conclusion, our findings indicate that D~2~R availability in the caudate and in the putamen are differentially affected with advancing PD. Chronic exposure to treatment with dopamine agonists, but not levodopa, suppresses striatal D~2~R availability, which may have relevance to caudate output signaling to frontal lobes and the occurrence of executive deficits, but not dyskinesias. Availability of D~2~Rs is not confined only to the striatum and previous PET studies have shown alterations in extra-striatal regions that may be implicated in the development of non-motor symptoms in PD ([@bb0075], [@bb0080], [@bb0125]). Hopefully, future studies will help understand the relevance of extra-striatal D~2~R system in the development of non-motor symptoms and the associations with exposure to dopaminergic treatment in patients with PD.
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[^1]: Disease duration has been accounted from time of first appearance of PD symptoms; LED~[l]{.smallcaps}-DOPA~ = levodopa equivalent dose; LED~DA~ = dopamine agonists equivalent dose; H&Y = Hoehn and Yahr; MMSE = Mini Mental State Examination; BDI-II = Beck Depression inventory; HRSD = Hamilton Rating Scale for Depression. SD = Standard Deviation.

[^2]: Δ% = percentage difference compared to healthy controls; BP~ND~ = non-displaceable binding potential; PD = Parkinson\'s disease.

[^3]: p \< 0.05.

[^4]: p \< 0.001.
